Industry reaction has been largely positive toward the final rule for Stage 2 meaningful use, but many acknowledge that even though there is relief in the timeline, many requirements will still be challenging to meet. The federal Centers for Medicare & Medicaid Services (CMS) issued the final rule for Stage 2 meaningful use under the American Recovery and Reinvestment Act/Health Information Technology for Economic and Clinical Health (ARRA-HITECH) Act last Thursday, Aug. 23.
Ferdinand Velasco, M.D., chief health information officer of the 25-hospital Texas Health Resources in Arlington, Texas, thinks that the public comments of his organization, as well as others, were heard, especially in regard to having fewer requirements in the final rule.
“I do think that the MU Stage 2 final rule and standards and certification rule continue to be ambitious, but, I think, reasonable and attainable,” says Velasco. “I don’t think it would have been realistic to the original timeframe that we could have started the reporting period on October 1, 2012; and in fact, now we have a little more time. Now there’s a three-month reporting period, and that gives the vendors and providers more space. I think it’s an acknowledgement of the concerns being expressed by the community around the original timeline.”
Much of everything in the proposed rule is still there, apart from a few tweaks here and there, says Jane Metzger, research principal of the Global Institute for Emerging Healthcare Practices in Waltham, Mass., a division of the Falls Church, Va.-based CSC. “I think comments in every cycle have always said, it’s too much—too long a list of things. And on that front, I don’t think Stage 2 gave too much relief,” she adds. “Another area of comment [is there] has been too little time. And until we got some of these clarifications in the final Stage 2 rule, the timeline had become ridiculous, because of all the delays in getting Stage 2 out and Stage 2 verification wasn’t up and running, and all of that. And I thought overall that there was relief there.”
Easing up on Patient Engagement, Interoperability
CMS did let up a bit on the requirement for patients to view, download and transmit their health information, lowering the threshold from 10 percent to 5 percent, which Velasco thinks is not an unreasonable requirement since the meaningful use incentive program is “quasi-voluntary.”
“I can well appreciate the perspective of those critical of that requirement, but that’s where healthcare is going in general,” he adds. “And providers increasingly are having to take some responsibility for their patients doing the right thing. So I think [CMS] is making a very clear statement that patient engagement, and interoperability, another one of those controversial areas, are key focus areas, despite the pushback from the healthcare providers.”
One requirement that was retained in the final Stage 2 rule was that eligible providers and hospitals conduct health information exchange with providers not on the same technology platform. However, CMS eased up and replaced the organizational and vendor limitations of exchanging information with another vendor to having providers conduct one or more successful data exchange tests with a “CMS designated test EHR” during the EHR reporting period.
“They’ve pared down the requirement to basically a yes/no question,” says Velasco. “And if you can’t do that, there’s also the CMS test you can use to test interoperability. So it is a challenging requirement, but not an onerous one. I’ve always maintained that HITECH was not a bailout in the way that the rest of the stimulus might have been. It’s meant to move the ball forward.”
This allowance for data exchange tests certainly helps in areas where there are dense market shares of one particular EHR vendor, which occurs many times in smaller communities, says Robin Raiford, research director in the Advisory Board’s IT Strategy Council. However, the capability to share information outside of a particular organization’s EHR system is particularly necessary in the case of snowbirds, those who spend part of the year in a warmer part of the country.
Clinical Quality Measures Still a Challenge
The specific requirements for clinical quality measures were not a part of the final rule for Stage 2; they have been disconnected from the meaningful use stages and will be published in October. “Clinical quality measures are no longer a core requirement, and that makes it a whole lot harder to sort out,” says Metzger. “And there are different rules and timelines for future Stage 1 attesters. So people who’ve already figured out Stage 1 and are still working toward it have to do a reality check. I think this makes it really hard for vendors.”